查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1916874

環肽庫市場按類型、產品形式、方法、給藥途徑、應用和最終用戶分類－全球預測（2026-2032 年）

Cyclic Peptide Library Market by Type, Product Format, Method, Route Of Administration, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，環肽庫市場價值將達到 34.2 億美元，到 2026 年將成長至 37.5 億美元，到 2032 年將達到 98.6 億美元，複合年成長率為 16.32%。

主要市場統計數據
基準年 2025 34.2億美元
預計年份：2026年 37.5億美元
預測年份：2032年 98.6億美元
複合年成長率 (%) 16.32%

透過結構和功能優勢，明確環狀胜肽庫在現代藥物發現流程和轉化研究中的戰略作用。

環肽庫已從學術實驗室中的一種小眾工具發展成為藥物發現和轉化研究流程中的戰略資產，重塑了研究人員進行標靶結合、分子設計和先導藥物最適化的方式。本文回顧了環肽的科學基礎和實際效用，重點介紹了其結構優勢，例如構象限制、更高的靶點特異性以及通常優於線性胜肽的代謝穩定性。此外，近年來展示技術、合成方法和計算建模的進步拓展了環肽的應用範圍，使其能夠對以往難以處理的複雜靶點類別進行高通量分析。

篩檢、結構測定和臨床應用的進展如何融合，將重塑環肽類藥物的發現模式

環肽研究領域正受到技術、方法和市場主導因素的共同作用而重塑，並由此帶來變革性轉變。首先，組合文庫設計和高通量篩檢的創新使得研究人員能夠精準地探索更大、更多樣化的化學空間，從而提高了針對複雜靶點的配體發現潛力。同時，質譜分析、基於片段的方法以及機器學習驅動的序列-功能模型的進步，使得研究人員能夠快速註釋先導化合物並早期預測其開發潛力，從而簡化了先導化合物化合物的篩選過程。

評估2025年美國關稅如何推動胜肽類研究生態系統的供應鏈重組與策略營運調整

美國2025年實施的政策調整和關稅措施，為環肽研究供應鏈的各個環節帶來了新的營運複雜性，其累積影響涵蓋了從原料採購到契約製造和合作研究協議的各個方面。更高的關稅和更嚴格的程序要求增加了某些試劑和特殊耗材的進口成本，迫使採購團隊尋求供應商多元化並重新評估庫存策略。為此，許多實驗室正在延長採購前置作業時間，盡可能儲備關鍵試劑，並尋找合格的替代供應商，以確保篩檢宣傳活動和合成作業的連續性。

深入的細分市場分析揭示了生物化學研究、結構生物學和治療亞領域如何以獨特的方式推動環肽藥物的發現和開發重點。

環肽研究的各個細分領域趨勢揭示了不同的促進因素和技術需求，這些因素會影響投資重點和專案設計。在生物化學研究領域，基礎檢測方法的開發和標靶結合研究建構了後續藥物發現活動所需的基礎知識，而結構生物學研究則利用晶體學和核磁共振技術來闡明結合模式和構象動態。這些基礎性研究共同支撐著合理的化合物庫建構和後續篩檢決策。

美洲、歐洲、中東和非洲以及亞太地區的區域創新叢集和基礎設施會影響營運選擇和夥伴關係策略。

區域趨勢對環肽生態系統的人才取得、基礎設施、監管互動和夥伴關係機會都有顯著影響。在美洲，強大的轉化基礎設施、密集的生物技術叢集和整合的臨床網路促進了藥物從發現到早期臨床評估的快速進展。這些生態系統的特點是接近性資本、擁有廣泛的CRO（受託研究機構）和CDMO（合約開發和生產組織）服務，以及許多促進技術轉移和商業化的舉措合作。因此，在該地區運營的機構通常會優先考慮快速迭代和與臨床相關人員的密切合作。

一個獨特的生態系統匯集了平台創新者、轉化生物技術公司和專業服務供應商，從而促進環肽藥物的發現和開發。

環肽技術的競爭格局是一個由成熟的藥物研發團隊、專業生物技術公司、平台提供者和服務機構組成的相互關聯的生態系統。提供展示技術、高效合成和整合篩檢服務的平台提供者對於提高藥物發現效率至關重要，而合成化學創新者和分析專家則為將先導化合物轉化為候選治療藥物所需的開發性提供見解。學術創業公司和敏捷的生物技術公司通常推動早期新穎性和應用導向創新，將機制見解轉化為差異化的化合物庫設計和標靶策略。

領導者可以採取切實有效、影響深遠的策略行動，以降低環肽計畫的風險，並加速其從發現到臨床準備的進程。

產業領導者應優先採取果斷行動，以增強韌性、加速轉化進程並最大化其環肽計畫的策略價值。首先，應儘早將結構生物學與高品質的生物物理檢驗相結合，以降低後續研發的失敗率並指南合理的化合物庫設計。早期投入資源進行正交檢驗和結構確認，可以顯著提高先導化合物篩選的信噪比，並將藥物化學研究集中在最有前景的骨架上。

一種透明且可重複的調查方法，結合了專家訪談、技術文獻綜合和透過三角測量法進行的分析檢驗。

本研究採用嚴謹的分析框架，整合一手和二手訊息，對環肽的現況得出平衡且可重複的結論。一手研究包括對來自學術機構、生技公司、合約服務機構和轉化研究領域的科學研究和商業領袖進行結構化訪談，以深入了解技術應用、營運挑戰和夥伴關係動態。此外，還對同行評審文獻、專利概況、會議報告和官方監管指南進行了技術審查，以佐證研究觀察結果，並結合已記錄的科學進展和政策背景。

整合策略要務和營運經驗，建立將環肽發現轉化為臨床和商業性影響的綜合管道

環肽庫融合了化學、結構生物學和轉化策略，為解決棘手標靶和治療難題提供了極具吸引力的機會。本文綜合的證據表明，成功並非僅取決於單一的技術能力，而是需要一種整合策略，將穩健的庫設計、早期結構檢驗和營運韌性相結合。此外，從影響供應鏈的政策變化到區域產能缺口等外部環境因素，都將對專案執行和夥伴關係的選擇產生重大影響。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

第8章：環肽庫市場（按類型分類）

  • 合成環肽
  • 天然環肽

9. 依產品形式分類的環狀胜肽庫市場

  • 脂肽
  • 環肽
  • 環狀二勝二肽

第10章 依方法論分類的環肽庫市場

  • 固相胜肽合成
  • 重組生物合成
  • 液相胜肽合成
  • 混合技術

第11章 依給藥途徑分類的環肽庫市場

  • 外用
  • 口服
  • 注射

第12章：環肽庫市場（按應用領域分類）

  • 治療
  • 研究與開發
  • 環境保護
  • 診斷生物感測器

第13章：依最終用戶分類的環肽庫市場

  • 製藥公司
  • 合約研究與製造組織
  • 生技公司
  • 學術研究機構

第14章 環肽庫市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 環肽庫市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國環肽庫市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章美國環胜肽庫市場

第17章：中國環肽庫市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bicycle Therapeutics Ltd
  • Boehringer Ingelheim International GmbH
  • Evotec SE
  • Merck & Co., Inc.
  • Novartis AG
  • PeptiDream Inc.
  • Pfizer Inc.
  • Roche Holding AG
Product Code: MRR-AE420CB153C5

The Cyclic Peptide Library Market was valued at USD 3.42 billion in 2025 and is projected to grow to USD 3.75 billion in 2026, with a CAGR of 16.32%, reaching USD 9.86 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.42 billion
Estimated Year [2026] USD 3.75 billion
Forecast Year [2032] USD 9.86 billion
CAGR (%) 16.32%

Defining the strategic role of cyclic peptide libraries in modern discovery pipelines and translational research through structural and functional advantages

Cyclic peptide libraries have moved from niche tools in academic labs to strategic assets for discovery and translational pipelines, shaping how researchers approach target engagement, molecular design, and lead optimization. This introduction frames the scientific foundations and practical utility of cyclic peptides, highlighting their structural advantages such as conformational constraint, enhanced target specificity, and often improved metabolic stability relative to linear counterparts. In addition, recent advances in display technologies, synthetic methods, and computational modeling have broadened the scope of cyclic peptide applications, enabling high-throughput interrogation of complex target classes previously considered intractable.

Beyond chemistry, the integration of cyclic peptide libraries with biophysical screening, structural determination techniques, and cell-based functional assays has reconfigured typical workflows. Teams now layer orthogonal validation steps early in discovery to de-risk hits and accelerate progression into optimization. As a consequence, program timelines are shifting toward modular, evidence-driven pipelines that prioritize on-target engagement and translatability. This evolution is particularly salient for organizations balancing exploratory research and translational outcomes, since cyclic peptides often serve as bridging modalities between small molecules and biologics, offering unique pharmacological profiles that can address unmet therapeutic needs.

Importantly, stakeholders must navigate a complex ecosystem that includes academic innovation, service providers, and platform developers. Cross-disciplinary collaboration and early investment in robust analytical and screening capacity are essential to extracting maximum value from cyclic peptide strategies. This introduction sets the stage for deeper analysis of the technological shifts, regulatory and policy considerations, segmentation dynamics, and regional variation that follow, framing cyclic peptide libraries as a pivotal element of modern discovery and therapeutic design.

How converging advances in screening, structural determination, and translational practice are reshaping discovery paradigms for cyclic peptide modalities

The landscape for cyclic peptide research is being reshaped by a convergence of technological, methodological, and market-driven forces that together constitute transformative shifts. First, innovations in combinatorial library design and high-throughput screening are enabling larger and more diverse chemical space to be explored with better fidelity, which in turn increases the probability of identifying ligands for challenging targets. Concurrently, improvements in mass spectrometry, fragment-based methods, and machine learning-driven sequence-to-function models are enabling rapid annotation of hits and early prediction of developability profiles, smoothing the path toward lead selection.

Second, structural biology advancements are creating new opportunities for rational cyclic peptide design. Enhanced cryo-electron microscopy, crystallography pipelines, and integrative modeling techniques now allow teams to visualize peptide-protein interactions at higher resolution and in more native-like contexts. As a result, structural insights are increasingly driving the iterative optimization cycle, reducing reliance on blind screening and accelerating hypothesis-driven chemistry.

Third, the regulatory and translational environment is adapting to accommodate peptides as distinct therapeutic modalities. Regulatory pathways, clinical trial designs, and formulation strategies are evolving in response to unique pharmacokinetic and delivery challenges that cyclic peptides present. Consequently, organizations are investing earlier in ADME profiling, stability testing, and targeted delivery approaches, recognizing that these investments materially influence program viability. Taken together, these shifts are altering how discovery programs are prioritized, resourced, and executed across academic, biotech, and industrial settings.

Assessment of how the 2025 United States tariff measures are inducing supply chain realignment and strategic operational adaptations across peptide research ecosystems

Policy shifts and tariff measures introduced by the United States in 2025 have introduced a new layer of operational complexity across the cyclic peptide research supply chain, with cumulative effects felt from raw material procurement to contract manufacturing and collaborative research arrangements. The increased duties and procedural requirements have elevated inbound costs for certain reagents and specialized consumables, prompting procurement teams to reassess supplier diversification and inventory strategies. In response, many laboratories are extending procurement lead times, stockpiling critical reagents where feasible, and qualifying alternative suppliers to maintain continuity of screening campaigns and synthetic operations.

Moreover, service providers that rely on international supply chains have adjusted pricing models and contractual terms to reflect higher compliance overhead and variable lead times. This has influenced the economics of outsourcing discovery activities, with some organizations bringing capabilities in-house to manage costs and timelines while others renegotiate service-level agreements to include contingency provisions. Regulatory compliance and customs complexity have also driven investment in supply chain transparency and enhanced vendor auditing to reduce the risk of disruptions.

Beyond immediate procurement effects, tariff-driven uncertainty has prompted strategic reconsideration of geographic sourcing, partnership structures, and manufacturing footprints. Organizations are increasingly weighing nearshoring or regional manufacturing partnerships to mitigate tariff exposure, particularly for late-stage peptide production where regulatory inspection alignment and quality assurance are critical. These adjustments highlight that policy instruments intended to address broad economic objectives can have cascading operational and strategic impacts on specialized research ecosystems, necessitating proactive mitigation and adaptive planning across the industry.

Deep segmentation analysis revealing how biochemical research, structural biology, and therapeutic subdomains uniquely drive cyclic peptide discovery and development priorities

Segment-level behavior within cyclic peptide research reveals differentiated drivers and technical requirements that influence investment priorities and program design. In biochemical research contexts, foundational assay development and target engagement studies create the baseline understanding necessary for subsequent discovery activities, while structural biology efforts leverage crystallography and nuclear magnetic resonance methodologies to resolve binding poses and conformational dynamics. Together these foundational disciplines inform rational library construction and inform downstream screening decisions.

In the drug discovery segment, activities bifurcate into hit identification and lead optimization phases, where high-throughput screening and hit triage converge with medicinal chemistry and iterative optimization to improve affinity, selectivity, and pharmacokinetic properties. This progression is tightly linked to structural biology outputs and analytical characterization, forming a feedback loop that accelerates decision-making. Within therapeutics development, multiple clinical domains show unique needs and challenges: cardiovascular applications focus on indications such as heart failure and hypertension with an emphasis on safety and chronic dosing profiles, infectious disease work spans bacterial, fungal, and viral targets where potency and resistance profiles are paramount, and oncology efforts address both hematological malignancies and solid tumor contexts where delivery, tumor penetration, and target specificity drive program design.

These segmentation dynamics underscore the importance of cross-functional expertise; success often depends on integrating biochemical, structural, and translational perspectives early in program initiation. Additionally, platform choices-whether based on display technologies, synthetic libraries, or computationally designed cyclic motifs-must align with the segment-specific objectives and downstream clinical requirements to maximize translational potential.

How regional innovation clusters and infrastructure across the Americas, Europe Middle East & Africa, and Asia-Pacific shape operational choices and partnership strategies

Regional dynamics exert a meaningful influence on access to talent, infrastructure, regulatory engagement, and partnership opportunities across the cyclic peptide ecosystem. In the Americas, strong translational infrastructure, dense biotech clusters, and integrated clinical networks facilitate rapid progression from discovery to early clinical evaluation. These ecosystems are characterized by proximity to capital, broad CRO and CDMO services, and numerous academic-industry partnerships that catalyze technology transfer and commercialization initiatives. Consequently, organizations operating here often prioritize rapid iteration and close collaboration with clinical stakeholders.

In Europe, the Middle East & Africa region, diverse regulatory regimes and a mixture of advanced academic centers with emerging biotech hubs create both opportunities and complexities. Fragmented regulatory pathways can slow pan-regional deployment, but centers of excellence in structural biology and peptide chemistry provide deep technical capabilities. Strategic alliances and translational consortia are common approaches to bridge capability gaps and accelerate access to specialized services. Policymakers and funders in several jurisdictions are also enabling innovation through targeted grants and translational programs aimed at de-risking early-stage modalities.

In the Asia-Pacific region, rapidly maturing biopharma clusters, growing contract service capacity, and competitive manufacturing ecosystems are reshaping global sourcing strategies. Organizations in this region are rapidly scaling analytical and manufacturing capabilities for peptides and are increasingly central to global supply chains. Collaboration models often emphasize cost-efficiency and volume capability, while rising investments in local talent and infrastructure are enabling more advanced discovery activities to be undertaken regionally. Collectively, these regional characteristics influence partner selection, operational design, and strategic investment decisions across the industry.

Characterization of the ecosystem where platform innovators, translational biotechs, and specialized service providers converge to enable cyclic peptide discovery and development

The competitive landscape for cyclic peptide technologies is characterized by a mixture of established pharmaceutical research groups, specialized biotechnology firms, platform providers, and service organizations that together form an interconnected ecosystem. Platform providers that offer display technologies, high-throughput synthesis, and integrated screening services are central to enabling discovery throughput, while synthetic chemistry innovators and analytical specialists provide the necessary developability insights required to transition hits toward therapeutic leads. Academic spinouts and nimble biotech companies often drive early-stage novelty and application-focused innovation, translating mechanistic insights into differentiated library designs and targeting strategies.

Service organizations and contract development partners play a crucial role by allowing discovery teams to scale capacity without large upfront capital expenditure, and their geographic footprint often dictates pragmatic decisions about where key activities are executed. Meanwhile, partnerships between platform innovators and therapeutic developers are increasingly common, creating co-development pathways that accelerate tool refinement and enable mutual access to specialized expertise. In this environment, differentiation arises from the ability to deliver integrated workflows, depth of analytical validation, and a track record of translational success that spans biochemical validation through to clinical candidate selection. Companies that can demonstrate reproducible, scalable processes and transparent data pipelines command strategic relevance across discovery and development partnerships.

Practical, high-impact strategic actions leaders can implement to de-risk cyclic peptide programs and accelerate translation from discovery to clinical readiness

Industry leaders should prioritize a set of decisive actions that strengthen resilience, accelerate translational progress, and maximize the strategic value of cyclic peptide programs. First, integrate structural biology and high-quality biophysical validation at the earliest feasible stage to reduce downstream attrition and to inform rational library design. By committing resources to orthogonal validation and structural confirmation early, teams can substantially improve the signal-to-noise ratio of hit triage and focus medicinal chemistry efforts on the most promising scaffolds.

Second, diversify supply chains and consider a hybrid model that balances in-house capability with trusted external partners. Near-term procurement and tariff volatility underscore the importance of supplier redundancy and contractual flexibility. Organizations should also invest in data-centric vendor evaluation and build contingency planning into service agreements to minimize operational disruptions.

Third, cultivate cross-disciplinary teams that blend peptide chemistry, structural science, computational modeling, and translational expertise to shorten decision cycles and improve developability assessment. Equally important is the development of clear go/no-go criteria tied to both scientific milestones and business objectives, enabling objective progression decisions and conserving resources for the highest-probability programs. Finally, pursue focused partnerships and co-development arrangements that align platform strengths with therapeutic domain expertise, thereby sharing risk while unlocking complementary capabilities and accelerating time-to-proof-of-concept.

Transparent and reproducible research methodology combining primary expert interviews, technical literature synthesis, and triangulated analytical validation

This research synthesizes primary and secondary inputs with rigorous analytical frameworks to produce a balanced and reproducible view of the cyclic peptide landscape. Primary research included structured interviews with scientific and commercial leaders across academic institutions, biotechnology firms, contract service organizations, and translational research units, providing qualitative insights into technology adoption, operational challenges, and partnership dynamics. These interviews were supplemented by technical reviews of peer-reviewed literature, patent landscapes, conference proceedings, and public regulatory guidance to ground observations in documented scientific progress and policy context.

Analytical methods included cross-validation of thematic findings through triangulation, where independent data sources and expert interviews were used to corroborate key conclusions. Case-study analysis of representative discovery programs provided practical examples of workflow integration, decision gates, and translational risk management. Throughout the methodology, emphasis was placed on transparency of assumptions, reproducibility of thematic coding, and clear documentation of interview protocols and source attribution. Quality control procedures included iterative review cycles with subject-matter experts to ensure technical accuracy and to surface divergent perspectives where consensus was not present.

Synthesis of strategic imperatives and operational lessons that establish an integrated pathway for translating cyclic peptide discoveries into clinical and commercial impact

Cyclic peptide libraries stand at the intersection of chemistry, structural biology, and translational strategy, offering compelling opportunities to address challenging targets and therapeutic gaps. The evidence synthesized here shows that success depends on more than isolated technological capability; rather, it requires an integrated approach that couples robust library design, early structural validation, and operational resilience. Additionally, the external environment-from policy shifts affecting supply chains to regional differences in capability-exerts meaningful influence on program execution and partnership choices.

Looking forward, organizations that cultivate cross-disciplinary expertise, adopt flexible sourcing strategies, and engage in targeted partnerships will be better positioned to convert cyclic peptide hits into high-potential leads. By embedding structural and biophysical validation early, aligning platform selection with therapeutic context, and planning proactively for operational disruptions, stakeholders can materially improve translational outcomes. In sum, cyclic peptides are a maturing modality with distinctive advantages, and their strategic deployment requires thoughtful orchestration across science, operations, and commercial planning.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cyclic Peptide Library Market, by Type

  • 8.1. Synthetic Cyclic Peptides
  • 8.2. Natural Cyclic Peptides

9. Cyclic Peptide Library Market, by Product Format

  • 9.1. Lipopeptides
  • 9.2. Cyclotides
  • 9.3. Cyclic Dipeptides

10. Cyclic Peptide Library Market, by Method

  • 10.1. Solid-Phase Peptide Synthesis
  • 10.2. Recombinant Biosynthesis
  • 10.3. Liquid-Phase Peptide Synthesis
  • 10.4. Hybrid Technology

11. Cyclic Peptide Library Market, by Route Of Administration

  • 11.1. Topical
  • 11.2. Oral
  • 11.3. Injectable

12. Cyclic Peptide Library Market, by Application

  • 12.1. Therapeutics
  • 12.2. Research & Development
  • 12.3. Environmental Protection
  • 12.4. Diagnostics & Biosensors

13. Cyclic Peptide Library Market, by End-User

  • 13.1. Pharmaceutical Companies
  • 13.2. Contract Research & Manufacturing Organizations
  • 13.3. Biotechnology Companies
  • 13.4. Academic Research Institutes

14. Cyclic Peptide Library Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cyclic Peptide Library Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cyclic Peptide Library Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Cyclic Peptide Library Market

18. China Cyclic Peptide Library Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Amgen Inc.
  • 19.6. Astellas Pharma Inc.
  • 19.7. AstraZeneca PLC
  • 19.8. Bicycle Therapeutics Ltd
  • 19.9. Boehringer Ingelheim International GmbH
  • 19.10. Evotec SE
  • 19.11. Merck & Co., Inc.
  • 19.12. Novartis AG
  • 19.13. PeptiDream Inc.
  • 19.14. Pfizer Inc.
  • 19.15. Roche Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CYCLIC PEPTIDE LIBRARY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CYCLIC PEPTIDE LIBRARY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY SYNTHETIC CYCLIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY SYNTHETIC CYCLIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY SYNTHETIC CYCLIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY NATURAL CYCLIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY NATURAL CYCLIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY NATURAL CYCLIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY LIPOPEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY LIPOPEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY LIPOPEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY CYCLOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY CYCLOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY CYCLOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY CYCLIC DIPEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY CYCLIC DIPEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY CYCLIC DIPEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY SOLID-PHASE PEPTIDE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY SOLID-PHASE PEPTIDE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY SOLID-PHASE PEPTIDE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY RECOMBINANT BIOSYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY RECOMBINANT BIOSYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY RECOMBINANT BIOSYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY LIQUID-PHASE PEPTIDE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY LIQUID-PHASE PEPTIDE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY LIQUID-PHASE PEPTIDE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY HYBRID TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY HYBRID TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY HYBRID TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ENVIRONMENTAL PROTECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ENVIRONMENTAL PROTECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ENVIRONMENTAL PROTECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY DIAGNOSTICS & BIOSENSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY DIAGNOSTICS & BIOSENSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY DIAGNOSTICS & BIOSENSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY CONTRACT RESEARCH & MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY CONTRACT RESEARCH & MANUFACTURING ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY CONTRACT RESEARCH & MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 133. GCC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GCC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. GCC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 136. GCC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 137. GCC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. GCC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. GCC CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 154. G7 CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. G7 CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. G7 CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 157. G7 CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 158. G7 CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. G7 CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. G7 CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 161. NATO CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. NATO CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NATO CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 164. NATO CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 165. NATO CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. NATO CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. NATO CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES CYCLIC PEPTIDE LIBRARY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA CYCLIC PEPTIDE LIBRARY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY METHOD, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA CYCLIC PEPTIDE LIBRARY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)